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           1. INTRODUCTION                       
Analysis is the study of the separation, identification and quantification of chemical 
components of natural and artificial materials. Analytical chemistry has been important since 
the early days of chemistry, providing methods for determining which elements and 
chemicals are present in the world around us. “Analytical chemistry is the chemistry 
discipline concerned with the chemical composition of materials. Analytical chemistry also is 
concerned with developing the tools used to examine chemical compositions” [1a, 27]. 
Pharmaceutical analysis plays an important role in quality assurance and quality control. 
  The discipline of analytical chemistry consists of [2a], 
I.  Qualitative analysis. 
II. Quantitative analysis. 
I Qualitative analysis:   
• It gives an indication of the identity of the chemical species in the sample. 
• Qualitative analysis seeks to establish the ways and means to detect the 
presence of a given element or    inorganic compound in a sample [30]. 
• Qualitative organic analysis researches to establish the method presence of a 
given functional group or organic compound in a sample. 
II Quantitative analysis: 
• Quantitative analysis deals with the development to establish the amount of a 
given element or compound in a sample. 
• Methods to determine of an absolute or relative abundance (often expressed as 
a concentration) of one, several or all particular substances present in a 
sample. 
Steps involved in quantitative analysis:  
 Chemical nature of the sample.  
 Selection of method. 
 Elimination of possible interferences. 
 Measurement of an analyte.  
 Calculation of results. 
 Estimation of reliability of the results (validation). 
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Factors affecting the choice of analytical methods  
 Type of analysis. 
 Nature of the material. 
 Interference from other components. 
 Concentration range to be investigated. 
 Accuracy. 
 Facilities available. 
 Time required for complete analysis. 
 
The analytical methods may be categorized into, 
                         ANALYTICAL METHODS [28] 
 
                           CHEMICAL METHODS        INSTRUMENTAL METHODS 
1.1) Chemical methods / Traditional methods:  
The chemical methods for separating and determining analytes still find use in many 
laboratories. For qualitative analysis the separated   components were then   treated with 
reagents that yield products that could be recognized by colours, boiling or melting point, the 
solubility in a series of solvents, odour, optical activities and their refractive indexes. For 
quantitative analysis, the amount of analyte was determined by gravimetric or titrimetric 
measurements. In gravimetric measurements, the mass of the analyte or some compounds 
produced from the analyte was determined [1b]. 
In titrimetric procedures, the volume or mass of a standard reagent required to react 
completely with analyte was measured.  
      a) Volumetric or Titrimetric  
i. Acid-base or Neutralization titrations. 
ii. Oxidation-Redution or  Redox titrations. 
iii. Precipitation titrations. 
iv. Complexometric titrations. 
v. Non-aqueous titrations. 
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     b) Gravimetric 
1.2) Instrumental methods:  
In the instrumental methods, the measurement of physical properties of analysis such 
as conductivity, electrode potential, light absorption and emission. Mass to charge ratio and 
fluorescence is also being used for quantitative analysis of a variety of inorganic, organic and 
biochemical analytes [1c]. Different physical properties are exploited in different analytical 
techniques are listed in table no.1. 
The first instrumental analysis was flame emissive spectrometry developed by Robert 
Bun sun and Gustav Kirchhoff who discovered rubidium and caesium in1860. 
   Table no. 1 Classification of analytical methods 
PHYSICAL PROPERTY 
MEASURED 
INSTRUMENTAL METHODS BASED ON 
MEASUREMENT OF PROPERTY 
Absorption radiation 
Emission of radiation 
Rotation of radiation 
Electrical Potential 
Electrical conductance 
Electrical current 
Thermal properties 
Spectrophotometry (X-ray, UV-Vis, IR, NMR)  
Fluorimetry, Flame photometry 
Polarimetry, ORD, CD. 
Potentiometry, Chrono-potentiometry 
Conductometry. 
Polarography, Amperometry. 
DTA, DSC etc. 
 
Chromatographic and electrophoretic techniques for the separation of components 
complex mixtures prior to their qualitative or quantitative determination. 
A)  Microbiological methods: 
  Biological assays in which the compounds being quantitated either depress or stimulate 
the growth of a sensitive test micro organism and those assays that employs enzymes [31]. 
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i) Diffusion assays 
ii) End point determination assays 
iii) Enzymatic assays 
B) Chromatography 
  i) History of Chromatography: 
The term chromatography (Greek: - Khromatos – colour and graphos –written) and its 
principles were first discovered by Mikhail Tswett in 1906[2b]. He primarily for the separation 
of plant pigments such as chlorophyll, carotenes and xanthophylls. Analytical chemistry 
became easier and more accurate through the development of paper chromatography.    
During 1970s, most chemical separations were carried out using a variety of 
techniques including open-column chromatography, paper chromatography and thin-layer 
chromatography. High pressure liquid chromatography was developed in the mid-1970s and 
quickly improved with the development of column packing materials and the additional 
convenience of on-line detectors. In the late 1970s, new methods including reverse phase 
liquid chromatography was employed for improved separation between very similar 
compounds [29]. By the 1980s, HPLC was commonly used for the separation of chemical 
compounds. New techniques improved separation, identification, purification and 
quantification far above the previous techniques.  
  ii) Theory:  
  Chromatography may be preparative or analytical [3]. The purpose of preparative 
chromatography is to separate the components of a mixture for further use. Analytical 
chromatography is done normally with smaller amounts of material and is for measuring the 
relative proportions of analytes in a mixture. The two are not mutually exclusive [4a]. 
            In this two mutually immiscible phases are brought into contact where one phase is 
stationary and other is mobile. Species in the sample undergo repeated physical interactions 
(partitions) between the mobile phase and stationary phase. The components are gradually 
separated into bands in mobile phase. It is an analytical chromatographic technique that is 
useful for separating ions or molecule that are dissolved in a solvent [4a]. 
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iii) Types of Chromatography – Based on principle    
 Adsorption Chromatography 
Adsorption chromatography is probably one of the oldest types of chromatography 
around. It utilizes a mobile liquid or gaseous phase that is adsorbed onto the surface of a 
stationary solid phase. As shown in the fig. no.1 the equilibrates between the mobile and 
stationary phase accounts for the separation of different solutes [5a]. 
Fig. no. 1 Solute adsorbed on stationary phase in adsorption chromatography 
 
                           
 
 
 
 
 
 
 Partition Chromatography 
 This form of chromatography is based on a thin film formed on the surface of a solid 
support by a liquid stationary phase. As shown in the fig. no. 2 solute equilibrates between 
the mobile phase and the stationary liquid [4b,14].  
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Fig. no. 2  Solute in liquid phase distributed on surface of solid support in partition 
chromatography 
                              
 
 Ion Exchange Chromatography 
 
The chromatographic medium is an ion exchange resin which is polymer containing 
fixed charged groups and replaceable counter ions of the opposite charge. When a sample 
containing organic or inorganic ions is passed down the column the ions of the same charge 
as the counter ions displace the counter ions into the mobile phase and are retained on 
column. Cationic and anionic exchange resins have positively and negatively charged counter 
ions respectively, and retard the migration of the sample cations and anions respectively. The 
mobile phase in ion exchange chromatography is usually an aqueous solution containing one 
or more electrolytes.   
In this type of chromatography, the use of a resin (the stationary solid phase) is used 
to covalently attach anions or cations onto it. Fig no.3 shows that the solute ions of opposite 
charge in the mobile liquid phase are attracted to the resin by electrostatic forces [4c].  
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Fig. no. 3  Ions exchanged with resins in ion exchange chromatography 
 
                    
 Molecular Exclusion Chromatography 
It is also known as gel permeation or gel filtration, this type of chromatography lacks 
an attractive interaction between the stationary phase and solute. The liquid or gaseous phase 
passes through a porous gel which separates the molecules according to its size. As shown in 
the fig. no. 4 the pores are normally small and exclude the larger solute molecules, but allow 
smaller molecules to enter the gel, causing them to flow through a larger volume. This causes 
the larger molecules to pass through the column at a faster rate than the smaller ones. 
 
           Fig. no. 4 Movement of solute molecules in molecular exclusion chromatography 
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 Affinity Chromatography 
 This is the most selective type of chromatography employed. It utilizes the specific 
interaction between one kind of solute molecule and a second molecule that is immobilized 
on a stationary phase. For example, the immobilized molecule may be an antibody to some 
specific protein. When solute containing a mixture of protein passes through molecule, only 
the specific protein is reacted to this antibody, binding it to the stationary phase is shown in 
the fig. no. 5. This protein is later extracted by changing the ionic strength or pH [5b].  
 
Fig. no. 5  Movement of molecules affinity chromatography 
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iv) CLASSIFICATION             
Gas chromatography  
 Mobile phase     Liquid chromatography  
Super critical fluid                                     
                                                                                                            chromatography  
 
 
Planar chromatography  
Column chromatography  
Chromatography                                                                         
Elution  
                                                                                                              
                                                 Development technique  Displacement 
  
Frontal 
    
                                                                                                               
Adsorption  
Partition  
Bonded phase  
   Separation mode   Ion exchange  
Size exclusion 
Affinity  
Micellar  
Complexation   
Counter current  
 
 
 
Techniques 
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v) Some special types of chromatographic techniques 
a. Chiral chromatography: 
 Chiral chromatography involves the separation of stereoisomers. In the case of 
enantiomers, these have no chemical or physical differences apart from being three-
dimensional mirror images. Conventional chromatography or other separation processes are 
incapable of separating them. To enable chiral separations to take place, either the mobile 
phase or the stationary phase must themselves be made chiral, giving differing affinities 
between the analytes. Chiral chromatography HPLC columns (with a chiral stationary phase) 
in both normal and reversed phase are commercially available [6]. 
b. Hydrophilic Interaction Liquid Chromatography (HILIC):  
This is somewhat similar to normal phase chromatography using a polar stationary 
phase such as silica or ion exchange materials but eluted with polar mobile phases or organic 
solvents and aqueous buffers. It is most commonly used to separate the polar analytes and 
hydrophilic peptides[7]. 
c. Hydrophobic Interaction Chromatography (HIC):  
Analogues to RPC except that mobile phases of low organic solvents content and high 
salt concentrations are used for the separation of proteins that can be easily denatured by 
mobile phases with high concentrations of organic solvents used in RPC. 
d. Electro Chromatography: 
 Uses capillary electrophoresis (CE) equipment with packed capillary HPLC column. 
The mobile is driven by the electromotive force from a high voltage source as opposed to a 
mechanical pump. It is capable of very high efficiency [25]. 
e. Super Critical Fluid Chromatography (SFC):  
Uses HPLC packed columns and a mobile phase of pressurized supercritical fluids 
(i.e. carbon dioxide with a polar organic solvent). Useful for non polar analytes and 
preparative applications where purified materials can be recovered easily by evaporating the 
carbon dioxide. HPLC pumps normal and GC type detectors are often used [26].  
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f. Ultra Performance Liquid Chromatography:  
In this technique, columns with smaller particles (1.7 micron) and instrumentation 
with specialized capabilities deliver mobile phase at 15000 Psi (1000 bar). Research is going 
on much smaller than one micron diameter particles capable of performing at 100,000 Psi          
(6800 bar) [11]. 
g. Fast protein liquid chromatography:  
Fast protein liquid chromatography (FPLC) is a term applied to several 
chromatography techniques which are used to purify proteins. Many of these techniques are 
identical to those carried out under high performance liquid chromatography, however use of 
FPLC techniques are typically for preparing large scale batches of a purified product[8]. 
 
h. Countercurrent chromatography: 
Countercurrent chromatography (CCC) is a type of liquid-liquid chromatography, 
where both the stationary and mobile phases are liquids [9]. The operating principle of CCC 
equipment requires a column consisting of an open tube coiled around a bobbin. The bobbin 
is rotated in a double-axis gyratory motion (a cardioid), which causes a variable gravity (G) 
field to act on the column during each rotation. This motion causes the column to see one 
partitioning step per revolution and components of the sample separate in the column due to 
their partitioning coefficient between the two immiscible liquid phases used. There are many 
types of CCC available today. These include HSCCC (High Speed CCC) and HPCCC (High 
Performance CCC). HPCCC is the latest and best performing version of the instrumentation 
available currently [10]. 
i. Other forms of low pressure liquid chromatography:  
Flash chromatography is a technique for sample purification using disposable glass 
NPC columns and mobile phase driven by gas-pressure or low-pressure pumps. 
C. Reversed phase chromatography: 
In 1960s, chromatographers started modifying the polar nature of silanol group by 
chemically reacting silica with organic silanes. The objective was to make less polar or non 
polar so that polar solvents can be used to separate water soluble polar compounds. Since the 
ionic nature of chemically modified silica is now reversed i.e. it is non polar and the nature of 
the phase is reversed. The chromatographic separation carried out with such silica is referred 
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to as reversed–phase chromatography. A large number of chemically bonded stationary 
phases based on silica are available commercially. Table no.2 lists some of the functional 
groups bonded in chemically modified silica. Silica based stationary phases are still most 
popular in reversed phase chromatography [17]. However, other adsorbents based on polymer 
(styrene-divinylbenzene copolymer) are slowly gaining ground. Simple compounds are better 
retained by the reversed surface, the less water-soluble (i.e. the more non polar). The 
retention decreases in the following order: aliphatic greater than induced dipoles (i.e. CCl4) > 
permanent dipoles (e.g. CHCl3) > weak lewis bases (ethers, aldehydes and ketones) > strong 
lewis bases (amines) > weak lewis acids (alcohols and phenols) > strong lewis acids 
(carboxylic acids). The retention increases as the number of the carbon atoms increases [4a]. 
As a general rule, the retention increases with increasing in contact area between 
sample molecule and stationary phase i.e. with increasing in number of water molecules 
which are released during the adsorption of a compound. Branched chain compounds are 
eluted more rapidly than their normal isomers.  
In reversed phase systems chemically bonded octadecyl silane (ODS) is alkaline with 
18 carbon atoms, it is the most popular stationary phase used in pharmaceutical industry. 
Since most of the pharmaceutical compounds are polar and water soluble, the majority HPLC 
methods for quality assurance decomposition studies, quantitative analysis of both bulk drugs 
and their formulations use ODS columns. The solvent strength in reversed phase 
chromatography is reversed from that of adsorption chromatography (silica gel) as stated 
earlier water interacts strongly with silanol groups, so that, adsorption of sample molecules 
become highly restricted and they are rapidly eluted as a result. Exactly opposite applies in 
reversed phase systems. Water cannot wet the non polar (hydrophobic) alkyl groups such as 
C-18 of ODS phase and therefore does not interact with the bonded moiety; hence water is 
the weakest solvent of all and gives slowest elution rate. The elution time (retention time) in 
reversed phase chromatography increases with increasing amount of water in the mobile 
phase. 
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Table no. 2  Various bonded phases used in HPLC [12c] 
Phase Structure Description 
 
Si 
 
 
 
 
        C1 
 
 
             
             
C2 
 
 
             
C3 
 
 
 
 
C4 
 
 
 
 
                
              −Si −O−Si−OH 
                                  
 
 
              
             −Si−O −Si −CH3 
             
              
                   
         −Si−O −Si −C2H5 
              
   
          
         −Si−O − Si −C3H7         
          
 
 
                                          
       −Si−O − Si –C4H9 
            
 
 
 
Silica                              
Classic normal phase material. 
Suitable for separating polar non-
ionic organic compounds. 
 
Reversed phase material. Unique 
selectively for polar and 
multifunctional compounds. Least 
retentive of all alkyl group bonded 
phase for non polar solvents. 
 
Reversed phase material, less 
retentive than C4, C8, or C18 more 
retentive than C1. 
 
 
Reversed phase material, used in 
hydrophobic interaction 
chromatography (HIC) of proteins 
and peptides. 
 
Reversed phase material, useful for 
ion-pairing chromatography offers 
less retention than C8 and C18 
phases for non polar solutes. When 
bonded to 300 Ao silica, it is an 
ideal phase for analyzing large 
proteins and hydrophobic peptides. 
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C6 
 
 
 
 
             
C8 
 
 
 
 
 
 
 
 
             
C18 
 
 
 
 
 
 
 
 
 
C6H5 
 
 
 
 
            
         −Si−O −Si –C6 H13 
              
 
 
              
         −Si−O −Si –(C7 H14)CH3 
             
 
 
 
 
 
 
               
            −Si−O −Si –(C17 H34)CH3            
 
 
 
 
 
 
 
 
        
     −Si−O −Si–(CH2)3 
 
 
 
Reversed phase material, useful for 
ion-pairing chromatography. Less 
retentive than C8 and C18. 
 
 
Reversed phase material, similar 
selectively to C18 but less retentive. 
Wide applicability (e.g. 
pharmaceuticals, nucleotides, 
steroids). When bonded to 300 Ao 
silica, it is an ideal phase for 
peptides, peptide mapping and 
small hydrophilic proteins. 
< 
 
Classic reversed phase material is 
most retentive for non-polar solutes 
and is excellent for ion-pairing 
chromatography. It is having wide 
applicability for the assay of 
nucleosides, nucleotides, steroids, 
pharmaceuticals, vitamins, fatty 
acids, and environmental 
compounds when bonded to 300 
Ao silica this phase perfect for 
separating small hydrophilic 
compounds. 
 
It is a reversed phase material and 
exhibits unique selectivity. It is 
useful for analyzing aromatic 
compounds. When bonded to 300 
Ao silica this phase is used for HIC.
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           CN 
 
 
 
 
 
 
 
 
           NH2 
 
 
                        
             
 NO2 
 
 
 
 
OH 
 
 
 
 
 
 
                                                                  
         −Si−O −Si –(CH2)3CN 
   
 
 
 
 
 
                                               
   −Si−O − Si – (CH2)3NH2 
 
 
 
 
              −Si−O −Si-NO2 
 
 
 
 Si                                         
  O −Si -(CH2)3OCH2(CHOH)2CH3 
 
 
 
 
 
<
It can be employed as either a 
reversed phase or normal phase 
material.  It is slightly polar and 
exhibits unique selectivity for polar 
copounds in both RP and NP 
modes.  It equillibrates very rapidly 
and suitable for gradient 
separations. It has many 
pharmaceutical applications (e.g., 
tricyclic anti depressants).  
 
<< 
Amino, Amino propyl silyl can be 
employed as reversed phase, 
normal phase or weak anion 
exchange material. Reversed 
phase: useful for separating 
carbohydrates. 
 
Normal pahse material. Separates 
aromatic compounds and 
compounds with double bonds. 
 
 
Diol, Glycerol can be employed 
either a reversed phase or normal 
phase material.  
Normal phase: Similar selectivity 
to silica not deactivated by small 
amounts of water. 
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a) INSTRUMENTATION        
The HPLC system consist of  
I Solvent degassing system. 
II Sample introduction systems. 
III A column and column packing material. 
IV Detector and recording unit. 
The components of HPLC system and their arrangements are shown in fig.no.6.  
 I. Solvent delivery system 
The mobile phase is pumped under pressure from one or several reservoirs and flows 
through the column at a constant rate, the direction of the solvent as shown in the fig.no.7 
with microparticulate packing; there is a high pressure drop across a chromatographic 
column. Eluting power of the mobile phase is determined by its overall polarity, the polarity 
of the stationary phase and the nature of the sample components. For normal phase 
 
 
   SAX 
 
 
 
 
          SCX 
 
 
 
 
             
WCX 
 
 
     −Si−O −Si- (CH2)3N(C H3)3 
 
 
 
 
       −Si−O −Si- (CH2)3SO2 OH 
 
 
 
 
−Si−O −Si- C H2COOH 
 
 Quaternary amines 
Strong base. Ion exchange 
material, strong anion exchangers 
(basic) are useful for separating 
nucleotides, nucleocides and 
organic acids. 
 
Sulphonic acid, Strong acid ion 
exchange material. Strong cation 
exchangers (acidic) are useful for 
separating organic bases. 
 
Carboxy methyl weak acid ion 
exchange material. Weak cation 
exchangers (acidic) are most useful 
for analyzing basic proteins and 
peptides.  
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separations, eluting power decreases with increasing solvent polarity. Optimum separating 
conditions can be achieved by making use of mixture of two solvents. Some other properties 
of the solvents, which need to be considered for successful separations, are boiling point, 
viscosity, detector compatibility, flammability and toxicity. 
The most important component of HPLC in solvent delivery system is the pump, 
because its performance directly effects the retention time and reproducibility. Among the 
several solvent delivery systems (direct gas pressure, pneumatic intensifier, reciprocating 
etc.). Reciprocating pump with twin or triple pistons widely used as this system gives less 
base line noise good flow rate reproducibility etc. The pump must be capable of generating 
pressure up to 5000 psi at pulse less flow rates of upto 3 ml/min for analytical operations.  
II. Sample introduction systems 
  Analyte introduction into the column are of two types namely a flowing stream and a 
stop flow injection. These techniques can be used with a syringe or an injection valve. 
Automatic injector is micro processor–controlled version of the manual universal injector. 
Usually, upto 100 samples can be loaded into the auto injector tray [4d]. The system 
parameters such as flow rates, gradient, run time volume to be injected etc. are chosen, stored 
in memory and sequentially executed on consecutive injections. 
III. Column and column packing materials  
  The heart of the system is the column. In order to achieve high efficiency of 
separation the column material (micro-particles 5-10 µm size) packed in such way that 
highest numbers of theoretical plates are possible. Silica (SiO2 × H2O) is the most widely 
used substance for the manufacturing of packing materials. It consists of a network of 
siloxane in cases (Si-O-Si) in a rigid three dimensional structure containing interconnecting 
pores [4e]. 
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 The silanol groups are surface of silica gives it a polar character, which is exploited 
adsorption chromatography using non–polar organic eluent. Silica can be drastically altered 
by reaction with organochlorosilanes or organoalkoxysilanes giving Si-O-Si-R linkages with 
the surface. The attachment of hydrocarbon chain to silica produces a non polar surface 
suitable for reversed phase chromatography where mixtures of water and organic solvents are 
used as eluents. The most popular material is octadecyl – silica (ODS-silica), which contains 
C18 chains, but materials with, C2, C4 and C6 chains are also available as shown in table no.2.     
 During manufacture, such materials may be reacted with small mono functional 
silanes (e.g. trimethylchlorosilane) to reduce further the number of silanol groups remaining 
on the surface (end-capping). There is a vast range of materials which have intermediate 
surface polarities arising from the bonding to silica of other organic compounds which 
contains phenyl, nitro, amino, and hydroxyl groups. Strong ion exchangers are also available 
in which sulfuric acid or quaternary ammonium groups are bonded to silica. The useful pH 
range for columns is between 2 and 8, since siloxane linkages are cleaved below pH 2 while 
at pH values above 8, silica may dissolve [4e].  
 In normal phase the separation is carried out using a non polar mobile phase over 
polar stationary phase; but in the reverse phase separation is achieved using a polar mobile 
phase. The pH of the mobile phase is adjusted to suppress the ionization of the drug and 
thereby increase the retention on the column. For highly ionized drugs ion pair 
chromatography is used. 
IV) Detectors: 
The main function of the detector in HPLC is to monitor the mobile phase coming out 
of the column, which in turn emits electrical signals that are directly proportional to the 
characteristics either of the solute or the mobile phase [12a]. The various detectors often used 
in HPLC may be categorized into three major heads, namely: 
 
i) Bulk-property detectors:  
They specifically measure the difference in some physical property of the solute 
present in the mobile phase in comparison to the individual mobile phase, for instance: 
(a) Refractive-index detectors 
(b) Conductivity detectors. 
INTRODUCTION                                                                                                                     CHAPTER-1                            
 
K. M. COLLEGE OF PHARMACY                 PHARMACEUTICAL ANALYSIS  Page 20 
 
(ii) Solute-property detectors:  
This type of detectors critically responds to a particular physical or chemical 
characteristic of the solute (in question), which should be ideally and absolutely independent 
of the mobile phase being used. But complete independence of the mobile phase is hardly to 
be seen, however, signal discrimination is good enough to enable distinctly measurable 
experimental procedures with solvent changes, such as: gradient elution. 
Ex. UV-detectors and fluorescence detectors. 
 
(iii) Multipurpose detectors: 
Besides, providing a high degree of sensitivity together with a broad linear-response-
attainable range, invariably a particular situation critically demands detectors of more 
selective nature in the domain of ‘analytical chemistry.’  ‘Pharmaceutical Analysis’ could be 
accomplished by using ‘multipurpose detectors’, such as: Perkin-Elmer ‘3D’ System that 
combines UV absorption, fluorescence and conductometric detection. 
 
(iv) Electrochemical detectors:  
Electrochemical detector in HPLC usually refers to either amperometric or 
coulometric detectors that specifically measures the current associated with the reduction or 
oxidation of solutes. As only a narrow spectrum of compounds undergoes electrochemical 
oxidation, such detectors are quite selective; which may be further enhanced by monitoring 
the potential applied to the detector so as to differentiate between various electroactive 
species. Naturally, electrochemical detection essentially makes use of conducting mobile 
phases, for instance: inorganic salts or mixtures of water with water-miscible organic 
solvents. 
 
b) Derivatization: 
 The main purpose of derivatization in HPLC is to improve detection specifically when 
determining traces of solutes in complex matrices, for example : 
i. Pharmaceutical substances lacking an UV-chromophore in the 254 nm region but   
possessing a reactive functional group [12b]. 
ii. Biological fluids e.g. blood, serum, urine; cerebrospinal fluid (CSF). 
iii. Environmental samples. 
Derivatization may be accomplished by two means, namely : 
a. Pre-column off-line derivatization. 
b. Post-column on-line derivatization. 
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These two methods shall be discussed briefly at this juncture: 
1. Pre-Column Off-Line Derivatization 
Merits:  
a. Requires no modification to the instrument i.e. a plus point when compared to the 
post-column methods. 
b. Imposes fewer limitations with regard to reaction time and conditions. 
Demerits:  
a. Formation of a stable and well defined product is an absolute necessity. 
b. Presence of excess reagent or by products may invariably interfere with separation. 
c. Very often derivatization may altogether change the chromatographic properties of the 
sample which facilitated separation [12b]. 
 
2. Post-Column On-Line Derivatization 
The following experimental parameters should be maintained namely: 
a. Derivatization performed in a special reactor strategically positioned between the 
column   and the detector. 
b. Reaction must be completed rapidly at moderate temperatures. 
c. Derivatization reaction need not even go to completion provided it can be made        
reproducible. 
d. No detector response should exist due to any excess reagent present. 
e. Reaction must be carried out in a medium other than the mobile-phase. 
Merit:  
a. Post-column-on-line derivatization is ideal for the separation.  
b. Detection processes can be optimized individually [12b]. 
 
D. Various Methods of quantitative analysis in HPLC 
                 
The sample or solute is analysed quantitatively in HPLC by either peak height or peak 
area measurements.  Peak areas are proportional to the amount of constant rate.  Peak heights 
are proportional to the amount of material only when peak width are constant and are 
strongly affected by the sample injection techniques [13].  Once the peak height or the peak 
areas are measured, there are five principle evaluation methods for quantifying the solute.  
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a. Calibration by Standards 
b. Internal Standard Method 
c. Area Normalization 
d. Standard Addition Method 
e. External Standard Method 
  
 
 
 
DRUG PROFILE                                                                                                                     CHAPTER-2                             
 
K. M. COLLEGE OF PHARMACY       PHARMACEUTICAL ANALYSIS  Page 23 
 
2. DRUG PROFILE 
 
 
2.1. AMLODIPINE: 
Amlodipine is long acting calcium channel blocker. It is dihydropyridine derivative 
used in treatment of hypertension and coronary artery disease [21a]. Because the parent 
compound had very poor oral bioavailability, amlodipine is available as the amlodipine 
besylate pro drug, which has improved oral absorption. The molecular structure of the 
amlodipine was shown in the fig no. 8. 
 
Fig no. 8   Chemical structure of amlodipine besylate 
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CAS number  : 88150-42-9  
Chemical Name : 2-[(2-Aminoethoxy)-4-(2-chlorophenyl)-1, 4-dihydro-6- 
methyl-3, 5- pyridine di-carboxylic acid-3-ethyl 5-methyl  
   esters [24a].                                                                                                             
Empirical Formula : C20H25CIN2O5 C6H6O3S 
Molecular weight : 567.1 gm/mol 
Description  : Amlodipine is a white crystalline powder. The partition         
coefficient for  amlodipine is 1.90 and the pKa is 8.6. 
Solubility  : Slightly soluble in water and sparingly soluble in ethanol.  
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Mechanism of action : 
Amlodipine is a dihydropyridine[23] calcium antagonist (calcium ion antagonist or 
slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular 
smooth muscle and cardiac muscle. Amlodipine binds to both dihydropyridine and non 
dihydropyridine binding sites. The contractile processes of cardiac muscle and vascular 
smooth muscle are dependent upon the movement of extracellular calcium ions into these 
cells through specific ion channels [22b]. Amlodipine inhibits calcium ion influx across cell 
membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac 
muscle cells. Negative inotropic effects can be detected in-vitro but such effects have not 
been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected 
by amlodipine. Within the physiologic pH range, amlodipine is an ionized compound 
(pKa=8.6), and its kinetic interaction with the calcium channel receptor is characterized by a 
gradual rate of association and dissociation with the receptor binding site, resulting in a 
gradual onset of effect. Amlodipine is a peripheral arterial vasodilator that acts directly on 
vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction 
in blood pressure. Amlodipine does also act as FIASMA (functional inhibitor of acid 
sphingomyelinase) [22a]. 
Pharmacokinetics [22c]:  
Absorption:   
Amlodipine is slowly and almost completely absorbed from the gastrointestinal tract. 
Peak plasma concentrations are reached 6-12 hour following oral administration. Its 
estimated bioavailability is 64-90 %. Absorption is not affected by food.  
Metabolism:  
Hepatic metabolized extensively (90 %) to inactive metabolites via the cytochrome 
P450 3A4 isozyme.  
Elimination:  
Amlodipine is extensively (about 90 %) converted to inactive metabolites via hepatic 
metabolism with 10% of the parent compound and 60 % of the metabolites excreted in the 
urine.  
Protein binding : 97. 5 % 
Bioavailability : 64 to 90 % 
Half-life  : 30 to 50 hours 
Excretion  : Renal 
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Adverse reaction:  
Following events are reported in < 0.1 % of patients: cardiac failure, pulse weakness, 
twitching, ataxia, hypertonia, migraine, cold and clammy skin, apathy, agitation, amnesia, 
gastritis, increased appetite, loose stools, coughing, rhinitis, dysuria, polyuria, parosmia, taste 
perversion, abnormal visual accommodation, and xerophthalmia [22c].  
Drug interaction:  
No drug interactions have been reported for amlodipine.  
Dosage and administration:  
Adults:  
The usual initial antihypertensive oral dose of amlodipine besylate tablets is 5 mg 
once daily with a maximum dose of 10 mg once daily. Small, fragile or elderly individuals or 
patients with hepatic insufficiency may be started on 2.5 mg once daily and this dose may be 
used when adding amlodipine besylate tablets to other antihypertensive therapy.  
Children:  
The effective antihypertensive oral dose in paediatric patients ages 6-17 years in 2.5 
mg to 5 mg once daily. 
Brand Names:    
Amlovasc 10 mg in the United Kingdom by Dr. Reddy's Laboratories. 
Norvasc 5 mg  in North America, China, Japan and Pakistan by Pfizer. 
ATECARD-AM 5 mg in India by Alembic Ltd. 
Amcard 5 mg in Bangladesh by Apex Pharma Ltd. 
Amlosun 5 mg in Bangladesh by Sun Pharmaceutical (Bangladesh) Ltd. 
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2.2. VALSARTAN:  
Valsartan (trade name Diovans) is an angiotensin-II receptor antagonist, acting on the 
AT-1 subtype. In the U.S, valsartan is indicated for treatment of high blood pressure, of 
congestive heart failure, and post-myocardial infarction [21b]. In 2005, Diovan was prescribed 
more than 12 million times in the United States. It is tetrazole derivative, used in treatment 
of hypertension. The molecular structure of the valsartan was shown in the fig no. 9. 
 
                   Fig no. 9  Chemical structure of valsartan  
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CAS number  : 137862-53-4    
Chemical Name : N-(1-Oxophenyl)-N-[[2’-(1H-tet-razol-5yl)[1,1’-biphenyl]-4-  
yl]methyl]-l-valine [24b].                  
Empirical formula : C24H29O3N5  
 
Molecular Weight : 432.51 gm/mol 
Description  : It is a white to practically white fine powder.  The partition  
coefficient for valsartan is 5.8 and the pKa is 8.15.  
Solubility  : It is soluble in ethanol and methanol and slightly soluble in   
    water.  
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Mechanism of action :  
Valsartan competes with angiotensin-II for binding at the AT1 receptor subtype [22d]. 
As angiotensin-II is a vasoconstrictor which also stimulates the synthesis of aldosterone, 
blockage of its effects results in a decrease in systemic vascular resistance. 
 
Pharmacokinetics [22e] :  
Bioavailability            :  25% 
Protein binding          :  95% 
Half-life                      :  6hours 
Absorption                 :  Absolute bioavailability 23% with high variability. 
Distribution               :  Volume of distribution is 17L 
Metabolism and Excretion: 
 Metabolism and excretion of valsartan is largely as unchanged drug (80%) and is 
minimally metabolized in humans [21c]. The primary circulating metabolite 4-OH – valsartan is 
pharmacologically inactive and produced CYP2C9. 4-OH – valsartan accounts for 
approximately 9 % of the circulating dose of valsartan. Although valsartan is metabolized by 
CYP2C9, CYP-mediated drug-drug interactions between valsartan and other drugs are 
unlikely. 
Excretion :  Renal 30 % and biliary 70 %  
Therapeutic use: In patients with impaired glucose tolerance, valsartan may decrease the 
incidence of developing type 2 diabetes mellitus [22].       
Trade names:   
                   Diovan 160 mg in US, UK and Australia by Novartis. 
                   Angiotan 160 mg in Pakistan Efroze. 
                   Valtan 320 mg  in India by Cipla. 
                   Valzaar 160 mg in India by Torrent Pharmaceuticals. 
Combination of both amlodipine and valsartan: 
 Amlodipine is a effective of hypertension in once daily doses of 2.5 mg - 10 mg  
while  valsartan is effective in doses of 80 mg – 3320 mg. In clinical trials with amlodiopine 
and valsartan tablets using amlodipine doses 5 mg -10 mg and valsartan doses of 160 mg – 
320 mg, the anti hypertensive effects increased with increasing doses. 
Trade names:  EXFORGE 10-320 mg in India by Pfizer. 
                         Calcitriol 10-320 mg in Switzerland by Cerbosis-pharma. 
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3. LITERATURE REVIEW 
Sedef Atmaca et al.,[32] developed a assay, which  involves derivatization of 
amlodipine with 4-chloro-7-nitrobenzofurazan (NBD-Cl), solid-phase extraction on a silica 
column and isocratic reversed-phase chromatography with fluorescence detection. The assay 
was linear over the concentration range of 0.25 – 18.00 ng/ml. Both interday and intraday 
reproducibility and accuracy were less than 11.80 % and 12.00 % respectively. 
 
Y. Fenag et al.,[33] developed a method after extraction by ethyl acetate using 
nicardipine as the internal standard, solutes are separated on a C-18 column with a mobile 
phase of methanol : 1% aceticacid (65:35). Detection is performed on an air pressure 
ionization single quadruple mass spectrometer equipped with an ESI interface and operated in 
positive-ionization mode. 
 
Kanakapura Basavaiah et al.,[34]  reported a new HPLC  determination was carried 
out on a reversed phase C-18 column using 0.1% ortho-phosphoric acid (pH 3) : acetonitrile 
(20 : 80) at a flow rate of 1.0 ml/min with UV-detection at 238 nm. In the HPLC method, a 
rectilinear relationship was observed between 7.55 – 241.6 µg/ml AMBL with a detection 
limit of 1.51 µg/ml and quantification limit of 3.02 µg /ml. 
 
K. R.  Naidu et al.,[35] described a stability indicating HPLC method and subsequently 
validated for simultaneous estimation of amlodipine (AMD) present as AMBL and BH from 
their combination product. The proposed RP-HPLC method utilizes a Zorbax SB    C-18 
column, mobile phase consisting of phosphate buffer and acetonitrile in the proportion of 65 : 
35 (v/v) with apparent pH adjusted to 7.0, and UV detection at 240 nm using a photodiode 
array detector. 
 
Fang Shungan et al.,[36] reported a HPLC method for the contents of amlodipine 
besylate by detection on UV light at 236 nm. The precisions (RSD) and the recovery (RSD) 
were detected. They have reported a good linear correlation within the range of   1.6 - 9.6 
μg/ml, r = 0.9995. This was precise with good recovery and suitable for quality control of 
amlodipine besylate tablet. 
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K. Raja Rajeswari et al.,[37] reported a simple, precise, accurate and rapid HPLC 
method  for estimation of  atorvastatin and amlodipine simultaneously, in combined tablet 
dossage form. The mobile phase used was a mixture of acetonitrile and 0.03 M phosphate 
buffer pH 2.9 (55 : 45% v/v). The detection of atorvastatin and amlodipine was carried out on 
dual absorbance detector at 240 nm and 362 nm respectively. 
 
M. D. Malesuik et al.,[38] reported a LC analyses on a RP-18 column using a mobile 
phase composed of 0.1 (v/v) orthophosphoric acid (pH 3.0) : acetonitrile (60 : 40, v/v) at a 
flow rate of 1.0 ml/min. The detection wavelength was at 238 nm. 
 
Afshin zarghi et al.,[39]  developed a chromatographic method for determination  of  
valsartan  in  human plasma  using a monolithic  column. The assay is based on protein   
precipitation   using acetonitrile and fluorescence detection. Reversed phase  conditions using 
a Chromolith Performance (RP-18) column with an isocratic mobile phase consisting of 
0.01 M disodium hydrogen phosphate buffer : acetonitrile (60 : 40  v/v)  adjusted  to  pH  3.5  
with  diluted  phosphoric  acid.   
 
D. F. Tian et al.,[40] reported a simple, reproducible and efficient reverse phase high 
performance liquid chromatographic method for simultaneous determination of valsartan and 
hydrochlorothiazide in tablets. Isocratic mode of separation with mobile phase containing 
methanol : acetonitrile : water : isopropyl alcohol (22 : 18 : 68 : 2; adjusted to pH 8.0 using 
triethylamine; v/v) was used. The flow rate was 1.0 ml/min and effluent was monitored at 
270 nm. The retention time for valsartan and hydrochlorothiazide were     3.42 min and 8.43 
min respectively.     
 
D. N. Vora et al.,[41] developed a fast, robust and stability indicating RP-HPLC 
method for simultaneous determination of  bisoprolol fumarate and amlodipine besylate in 
tablets. The mobile phase was mixture of 25 mM ammonium acetate adjusted to pH 5.0 and 
methanol (65 : 35) at 0.8 ml/min. The stationary phase was Luna C-18 column. UV detection 
was performed at 230 nm. Retention time was 1.45 and 3.91 min for bisoprolol and 
amlodipine respectively. 
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Hanaa M. Abdel Wadood et al.,[42] reported two simple and sensitive 
spectrofluorometric methods for determination of AMBL in tablets. The first method is based 
on the condensation reaction of AMBL with ninhydrin and phenylacetaldehyde in buffered 
medium (pH 7.0), resulting in formation of a green fluorescent product. This exhibits 
excitation and emission maxima at 375 and 480 nm respectively. The second method was 
based on the reaction of AMBL with 7-chloro-4-nitro-2, 1, 3-benzoxadiazole (NBD-Cl) in a 
buffered medium (pH 8.6) resulting in formation of a highly fluorescent product, which was 
measured fluorometrically at 535 nm (λex, 480 nm). 
 
R. Sunil Dhaneshwar et al.,[43] developed a TLC method for simultaneous 
quantitation of AMBL and VAL as the bulk drug and in tablet dossage forms. 
Chromatographic separation of the drugs was performed on aluminum plates pre-coated with 
silica gel 60 F254 as the stationary phase and the solvent system consisted of toluene : 
methanol : acetic acid 7 : 3 : 0.1 (v/v/v). Densitometric evaluation of the separated zones was 
performed at 244 nm. 
 
S. S. Chitlange  et al.,[44] described a precise, accurate and reproducible reverse phase 
high performance liquid chromatographic (RP-HPLC) method for simultaneous estimation of 
AMBL and VAL on RP C-18 column using acetonitrile : phosphate buffer (0.02 M, pH 3.0), 
(56 : 44 v/v) as mobile phase at a flow rate of 1.0 ml/min and the detection wavelength was 
234 nm. The retention time for AMBL and VAL was found to be 3.07 min and 6.20 min 
respectively. This method was also used for the determination of AMBL and VAL in the 
presence of their degradation products formed under variety of stress conditions. 
 
WANG Zheng-yu et al.,[45]  developed a simple and specific chromatographic method 
by using column of phenomenex ODS C-18  was used. The detection wavelength was at 239 
nm. The relationship between response and the concentration on the range of 9.952 ～99.520 
mg/l was linear with the correlation coefficient of 0.9999. The average recovery were     
99.09 %, 100.4 % and 101.2 %, RSD = 0.12 %.  
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 Zong-Zhu Piao et al.,[46] reported the valsartan concentration in human plasma 
samples using high performance liquid chromatography (HPLC) combined with ultraviolet 
(UV) detection. After a simple protein precipitation using methanol, the analytes were 
separated on a phenomenex Luna C-18 column using 42 % acetonitrile with 15 mg potassium 
dihydrogenphosphate in water (pH 2.0, adjusted with phosphoric acid) as the mobile phase at 
a flow rate of 1.2 ml/min was employed. 
 
A. V.  Ramani  et al.,[47] developed a high-throughput, simple, highly sensitive and 
specific LC-MS/MS method, for simultaneous estimation of simvastatin acid (SA), AMBL 
and  VAL with 500 µL of human plasma using deuterated simvastatin acid as an internal 
standard (IS). The chromatographic method was standardized with an X-Terra C-18 column. 
Mobile phase consisting of 0.02 M ammonium formate (pH 4.5) : acetonitrile (20:80, v/v) at 
a flow rate of 0.50 ml/min.  
 
G. Chaudhari et al.,[48]  described a RP-HPLC method for simultaneous estimation of 
VAL and AMBL from their combination dossage form. Column used was X-Terra RP-18 by 
gradient elution. Mobile phase consisted mixture of solution A (0.02 % trifluoro acetic acid) 
and solution B (water : acetonitrile : trifluoro acetic acid, 400 : 600 : 1, v/v/v) with flow rate 
of 1.5 ml/min and UV detection was carried out at 237 nm and 265 nm for AMBL and VAL 
respectively. The described method was linear over the range of 1.6-240 µg/ml and 1-30 
µg/ml for VAL and AMBL, respectively. The mean recoveries were 100.12 % and 99.72 % 
for VAL and AMBL respectively. 
 
S. U. Kokil et al.,[49]  developed a sensitive ion-paired reverse phase liquid 
chromatographic method for the simultaneous estimation of nebivolol hydrochloride and 
valsartan in their capsule formulation. The chromatographic method was standardized using a 
HIQ silica C-18 column with UV detection at 289 nm and flow rate of 1 ml/min. The mobile 
phase consisting of methanol : water (80 : 20 v/v) with addition of 0.1 % 1-hexanesulfonic 
acid monohydrate sodium salt as an ion-pairing reagent was selected. 
 
  Vamsikrishna Reddy et al.,[50] invented a new HPLC method and validated for the 
determination of valsartan in rabbit plasma. Separation was carried out on a reverse phase   
C-18 column, using a mixture of acetonitrile and 10 mM phosphate buffer (pH 3.0) in the 
ratio of 40 : 60 (% v/v)  at a flow rate of 1.0 ml/min with UV detection at 250 nm with run 
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time of 20 min. Telmisartan was used as internal standard (IS). The extraction efficiency of 
valsartan from rabbit plasma samples was ranged from 96.07 % to 98.1 %. 
 
A. Azza Moustafa et al.,[51] have developed  two simple, sensitive, and specific high-
performance liquid chromatography and thin-layer chromatography methods for the 
simultaneous estimation of AMBL and VAL. Separation by HPLC was achieved using a X-
Terra C-18 column and methanol : acetonitrile : water : 0.05 % triethylamine in a ratio 
40:20:30:10 by volume as mobile phase, pH was adjusted to 3 ± 0.1 with O-phosphoric acid. 
The flow rate was 1.2 ml/min. The TLC method used silica gel 60 F254 plates. The optimized 
mobile phase was ethyl acetate : methanol : ammonium hydroxide (55:45:5 by volume). 
Compounds were quantified densitometrically at 237 nm. 
 
CH. M. M. Prasada Rao et al.,[52]  developed a chromatographic method for 
quantization of amlodipine besylate and metoprolol succinate from bulk drug and 
pharmaceutical formulations using a mobile phase consisting mixture of 0.02 M phosphate 
buffer solution and acetonitrile as 80 : 20 at the flow rate of 1 ml/min. An Inertsil ODS-CV 
column was used as stationary phase. The retention times of amlodipine besylate and 
metoprolol succinate were 3.92 min and 10.43 min.   
 
Gaurav Patel et al.,[53] described a RP-HPLC method for the simultaneous estimation 
of amlodipine besylate and hydrochlorothiazide in combine dossage form. The mobile phase 
used was a combination of water : methanol (70 : 30). The detection of the combined dossage 
form was carried out at 245 nm and a flow rate employed was 0.5 mL/min. The retention 
time for amlodipine besylate and hydrochlorothiazide was found to be 6.95 min and 2.65 min 
respectively. 
 
K. R. Gupta et al.,[54]  reported a validated method for the simultaneous estimation of 
valsartan and amlodipine and in their combined dossage form by UV spectrophotometric 
methods. The method A employs estimation of drugs by simultaneous equation method 
(SEM) using 250 nm and 238 nm i.e. λmax values for VAL and AMBL respectively. 
Estimation of drugs by absorption correction method (ACM) at 360 nm i.e. λmax values of one 
drug and 236 nm an isobestic wavelength. VAL and AMBL individually and in mixture 
follow Beer’s law over the concentration range 5-30 µg/ml at all the selected wavelengths. 
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 D.  Kul  et al.,[55]  developed for two-component mixtures of AMBL and VAL were 
analyzed by HPLC and the ratio spectra of the first derivative spectrophotometric technique. 
Spectrophotometric method depends on the first derivative of the ratio-spectra by 
measurements of the amplitudes at 234 nm for VAL and 351 nm for AMBL. In the HPLC 
method, C-18 RP column with the mobile phase methanol - acetonitrile - NaH2PO4.H2O 
buffer, 5 ml/l triethylamine and adjusted to pH 3.0 at 2.0 ml/min flow rate was used to 
separate both compounds with detection at 254 nm. 
 
Moses Prince Francis et al.,[56] developed a LC-MS method on a C-18 analytical 
column, the mobile phase used was acetonitrile and 10 mM ammonium acetate in the ratio of 
90 : 10 v/v and the retention times were 0.829 and 1.281 min for azithromycin (Internal 
standard) and amlodipine respectively. 
 
 N. K. Ramadan et al.,[57]  reported three simple and sensitive methods for the 
determination of a mixture of AMBL and VAL without prior separation. In one method 
includes first derivative of ratio spectra technique was adopted by measuring its amplitude at 
255.5 nm and 290 nm. In another technique 242 nm was considered as isobestic point and 
360 nm for measuring the concentration of AMBL. The third method was precise ratio 
subtraction technique for the determination of VAL at its λmax 250 nm in presence of AMBL 
which was determined as mentioned at 360 nm. 
 
R. A.  Shaalan  et al.,[58] described a simple, sensitive and reliable spectrofluorimetric 
method for the simultaneous determination of the two antihypertensive drugs, AMBL and 
VAL in their combined tablets. In this method the native fluorescence was measured at λem 
455 nm and λem 378 nm by exciting at 360 nm and 245 nm for AMBL and VAL respectively. 
Regression analysis showed good correlation between fluorescence intensity and 
concentration over the concentration ranges 0.2-3.6 and 0.008-0.080 µg/ml for AMBL and 
VAL respectively. 
 
S. K. Patro et al.,[59] developed a new  RP-HPLC method for the determination of 
valsartan in pure and tablet forms. The method reports a linear response for concentrations in 
the range of 50-175 µg/ml using 0.01 M NH4H2PO4 (pH 3.5) buffer : methanol [50 : 50] as 
the mobile phase with detection at 210 nm and a flow rate of 1 ml/min and retention time 
11.0 min. 
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G. Thanusha et al.,[60] described a reverse phase high performance liquid 
chromatographic method for the quantitation of valsartan in both pure and pharmaceutical 
dossage forms. A venusil XBP C-18 column in isocratic mode with mobile phase containing 
0.1 M phosphate buffer : acetonitrile (20 : 80) at the flow rate of 1.0 ml/min and the effluents 
were monitored at 273 nm. The retention time of valsartan was found to be 4.95 min. 
 
 D. U. Vinzuda et al.,[61]  urbanized a method by using thermo-hypersil ODS column. 
The mobile phase comprised of water : acetonitrile : glacial acetic acid (5 : 5 : 0.01). The 
flow rate was set as 1.0 ml/min and effluent was detected at 273 nm. The retention time of 
valsartan was found to be 4.6 min. 
 
Alnajjar et al.,[62] developed a capillary electrophoresis method and validated for the 
simultaneous determination of AMBL and VAL in pharmaceuticals and human plasma using 
a UV photodiode array detector. Optimal conditions were 25 mM phosphate buffer at pH 8.0, 
injection time 10.0 s, voltage 25 kV, and column temperature 25 oC, with detection at        
214 nm. The method was found to be linear in the range of 1.035 mg/l and 1.0350 mg/l, with 
weighted regression 0.9999 and 0.9994, for AMBL and VAL respectively. Validation of the 
method showed acceptable intraday and interday accuracy (85.595.3) and precision (RSD-
1.644.2) in pharmaceutical formulation and human plasma analysis. 
 
Arabinda Patnaik et al.,[63] have quantified AMBL by HPLC method using 
Microbondapak, C-18 column in the study. Mobile phase of methanol : phosphate buffer of 
pH-3 (65 : 35)  at a flow rate of 1 ml/min. Detected at 210 nm. 
 
 A.  Ibrahim Darwish et al.,[64] described highly sensitive HPLC method with 
fluorescence detection and on-line emission wavelength switching for the simultaneous 
determination of VAL and AMBL in human plasma. Irbesartan (IRB) was used as internal 
standard. Separations were performed in low pressure gradient mode on Hypersil phenyl 
analytical column using a mobile phase consisting of phosphate buffer (pH 4.0 ± 0.1) : 
acetonitrile : methanol (60 : 30 : 10, v/v/v)  at a flow rate of 0.8 ml/min. The detection of 
VAL and IRB (IS) was carried out at 253 nm (for excitation) and 374 nm (for emission). 
After elution of VAL and IRB, the detection wavelengths were switched on-line to 393 nm 
(excitation) and 446 nm (emission) for detection of AMBL. 
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V. Bhaskara Raju et al.,[65]  have estimated VAL by using a chromatographic method 
which was standardized using a X-terra C-18 column. The mobile phase consisting of a 
mixture of phosphate buffer pH 3 and acetonitrile in the ratio of 50 : 50 v/v was selected. UV 
detection was carried at 210 nm and flow rate of 1 ml/min. The method was validated for its 
sensitivity, linearity, accuracy and precision. 
 
Bobbarala  Varaprasad  et al.,[66] developed a simple and accurate RP-HPLC method 
for the simultaneous estimation of hydrochlorothiazide, amlodipine besylate and valsartan by 
using C-18 column with a simple gradient elution using mobile phase comprising of 0.01 M 
potassium dihydrogen phosphate and acetonitrile. Flow rate was 1.0 ml/min and the detection 
was monitored out by UV detector at 237 nm. 
 
Della Grace Thomas Parambi et al.,[67]  developed a method for the quantitation of 
valsartan in tablet dossage form on a C-18 column using a mobile phase consisting of 
ammonium dihydrogen phosphate buffer : methanol (33.5 : 66.5) adjusted to pH 3 with 
formic acid at a flow rate of 1.0 ml/min  and detection at 265 nm. The retention time of 
valsartan was found to be at 11.9 min.  
 
K. Anandakumar et al.,[68] developed a new simple, accurate, and sensitive            
UV-spectrophotometric absorption correction method for simultaneous determination of 
AMBL, VAL and HCTZ  in bulk and in combined dossage form. Methanol and distilled 
water were used as solvents. The wavelengths selected for the analysis were 365 nm, 250 nm 
and 315 nm for AMBL, VAL and HCTZ respectively. Beer’s law obeyed the concentration 
range of 1-32 µg/ml, 4-40 µg/ml and 2-20 µg/ml for AMBL, VAL and HCTZ respectively. 
 
Lakshmanarao et al.,[69] described a RP-HPLC method for simultaneous 
determination of valsartan and hydrochlorothiazide in tablets. Isocratic mode of separation 
with mobile phase containing acetonitrile : phosphate buffer pH 3.0 in 1:1 ratio was used. 
The flow rate was 0.8 ml/min and effluent was monitored at 225 nm. The retention time and 
linearity range for valsartan and hydrochlorothiazide were (5.59 min, 2.36 min) and (10-50 
µg/ml, 10-50 µg/ml) respectively. 
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Nashwah gadallah Mohamed et al.,[70] developed a method for simultaneous 
determination of AMBL and VAL without previous separation. In this method amlodipine in 
methanolic solution was determined using zero order UV spectrophotometry by measuring its 
absorbence at 360.5 nm without any interference from valsartan. Valsartan spectrum in zero 
order is totally overlapped with that of amlodipine. First, second and third derivative could 
not resolve the overlapped peaks. The first derivative of the ratio spectra technique was 
applied for the measurement of valsartan. The ratio spectrum was obtained by dividing the 
absorption spectrum of the mixture by that of amlodipine, so that the concentration of 
valsartan could be determined from the first derivative of the ratio spectrum at 290 nm.  
 
 
Ola Moustafa Abdallah et al.,[71] developed  three methods for simultaneous 
determination of amlodipine and valsartan without previous separation. The first method 
depends on first derivative of the ratios spectra (DD1) by measurements of the amplitudes at 
234.5 nm and 247 nm for amlodipine using 30 μg/ml of valsartan as a divisor and at   282 nm 
and 292 nm for valsartan using 80 μg/ml of amlodipine as a divisor. The second method 
describes the use of multivariate spectophotometric calibration for the simultaneous 
determination of the analyzed binary mixture, where the resolution is accomplished by using 
partial least squares (PLS) regression analysis. In the third method, HPLC separation was 
performed by using reversed phase column and a mobile phase composed of acetonitrile: 
KH2PO4 (50 : 50 v/v) adjusted to pH 3.5 by phosphoric acid. 
 
 
P. V. Santosh Kumar et al.,[72]  reported a chromatographic method for the estimation 
of valsartan in bulk drugs and tablet formulation. The chromatographic method was 
standardized using a Kromasil C-18 column. The mobile phase consisting of a mixture of 
phosphate buffer and acetonitrile in the ratio of 55 : 45 v/v was selected.  Detection was 
carried at 233 nm and flow rate of 1 ml/min.  
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  Susheel John Varghese et al.,[73] reported HPLC and HPTLC-densitometric methods 
for simultaneous determination of AMBL, VAL and HCTZ in combined tablet dossage form. 
RP-HPLC analysis was performed on a Phenomenex Luna C-18 column, using a mobile 
phase consisting of 10 mM ammonium acetate buffer (pH 6.7) and methanol in solvent 
gradient elution for 20 min at a flow rate of 1 ml/min. Quantification was carried out using a 
photodiode array UV detector at 238 nm. HPTLC analysis was carried out on an aluminum-
backed sheet of silica gel 60F254 layers using chloroform : glacial acetic acid : n-butyl acetate 
(8 : 4 : 2, v/v/v) as the mobile phase. Quantification was achieved with UV densitometry at 
320 nm. 
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4. AIM AND PLAN OF WORK 
 
  Combination therapy in the treatment of hypertension as an appropriate treatment 
option is receiving boarder acceptance amongst the clinical community. Mono therapy is 
often not sufficient to normalize blood pressure since the goal of treatment is to normalize 
both systolic and diastolic blood pressure. A hypertension treatment guideline recently issued 
by the European Society of Hypertension and European Society of Cardiology or, in the 
Guide to Management of Hypertension 2008 issued by the Australian Heart Foundation 
recommends the combination therapy. 
It is proposed that these double combination tablets will be indicated as a substitution 
therapy in patients (i.e. patients are not to be started on this combination therapy) for the 
treatment of hypertension. As a replacement therapy in patients whose blood pressure is 
adequately controlled on amlodipine and valsartan used as individual or combination 
therapies.  
        Amlodipine is used in treatment of hypertension and coronary artery disease [21a,]  , 
and valsartan used for treatment of high blood pressure, of congestive heart failure, and post-
myocardial infarction[21b]. 
Literature survey reveals the availability of some methods for estimation of 
amlodipine besylate (AMBL) and valsartan (VAL) includes UV spectrometry, RP-HPLC and 
HPTLC alone are in combination with other drugs. Only very few HPLC estimations have 
been reported in the literature for the determinations of amlodipine and valsartan present in 
bulk, formulations and biological fluids.   
The existing methods are inadequate to meet the requirements, hence it is proposed to 
improve the existing methods and to develop new methods for the simultaneous estimation of 
amlodipine and valsartan in pharmaceutical dosage forms.  
The main objective for that is to improve the conditions and parameters, which could 
be easily adopted in the validation process. 
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5. EQUIPMENT AND CHEMICALS  
 
5.1 Drug sample  
 Amlodipine and valsartan sample obtained from HETERO Drug Laboratories Pvt., 
Ltd., Hyderabad.                                                                                                                              
  
5.2 Instruments used for the study:  
 
1. Waters separation module with Waters 2487 dual wavelength detector equipped with 
EMPOWER software.  
2. Sonica ultra sonic cleaner- model 2200 MH 
3. ELICO – pH meter model L1610 
4. Shimadzu AUX- 220 digital balance 
 
5.3 Chemical Reagents required: 
 
REAGENT NAME GRADE MANUFATURE 
Triethylamine AR Grade Merck, New Delhi. 
Sodium Hydroxide AR Grade Central drug house LTD., 
Mumbai. 
Potassium hydrogen phosphate AR Grade Spectrum, Mumbai. 
Orthophosphoric acid AR Grade Merck, New Delhi. 
Hydrochloric acid AR Grade SD fine Chem. LTD., 
Hyderabad. 
Acetonitrile HPLC Grade Merck, New Delhi. 
Methanol HPLC  Grade Merck, New Delhi. 
Water Milli-Q Milli pore, In house. 
 
 All the solutions were degassed and filtered through 0.22 µ PVD filter. 
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6. METHOD DEVELOPMENT 
  In case of analytical method development and for drugs analysts should decided 
whether the given analytical method is suitable for the assay of the drug. The method 
development of new improved method usually trailers existing approaches and 
instrumentation to the current analyte, as well as to the final needs or requirements of the 
method.  
     In the development stage, decision regarding choice of column, mobile phase, 
detectors and method of quantitation must be addressed. In this way, development 
considers all the parameters pertaining to any methods [15]. 
 
6.1. Different steps in method development time line:  
 
It includes percentage of time spent on the each stage. In this approach, three 
critical components of HPLC method (sample preparation, HPLC analysis and 
standardization) are investigated [16]. 
Step 1: Method objective should be to determine the goals for method development                             
            (Intended use of the method) and to understand the chemistry of the analytes   
            and the drug product. 
Step 2:Development of preliminary HPLC conditions to achieve minimally acceptable  
            separations. These HPLC conditions will be used for all subsequent method  
            development experiments. 
Step 3:Development of suitable sample preparation scheme for the drug product. 
Step 4:Determination of appropriate standardization method and the use of relative  
            response factors in calculations. 
Step 5:To identify the weakness of the method and to optimize the method through  
            experimental design. Understand the method performance with different  
            conditions, different instrument set up and different samples. 
Step 6:Complete method validation according to ICH guidelines [16]. 
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The objective of this experiment was to optimize the assay method for 
simultaneous estimation of amlodipine and valsartan based on the literature survey made 
and the methods given in official pharmacopoeias. Trials done for optimization are as 
follows:  
 
6.2. Trials 
i. Trial 1:  
Buffer preparation:  
1.0 ml of orthophosphoric acid was mixed with 1000 ml of Milli-Q water, and 
shake for 15 min. Then filtered through 0.22 µ nylon membrane filter and degassed.  
 
Mobile phase A                                 : Buffer  
Mobile phase B                                 : Acetonitrile: methanol (1 : 1).  
 
Chromatographic conditions           
Column              : Symmetry C-18, (150 × 3.4 mm, 5 µ)  
Detector wavelength             : 225 and 237 nm 
Column temperature              : 40 oC  
Injection Volume              : 10 µL 
Flow rate                        : 1.2 ml/min  
Runtime               : 25 min  
Gradient Programme:  As shown in the table no. 3 
Table no. 3 Gradient programme (Trial 1) 
 
Time(min) %A %B 
0.00 90 10 
18.00 20 80 
19.00 90 10 
25.00 90 10 
 
Observation: 
           Peak shapes were not satisfactory for both amlodipine and valsartan and the 
retention time of amlodipine and valsartan were found to be 10.05 and 15.216 min 
respectively. 
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ii. Trial 2:  
 In this trial almost similar conditions were employed except the mobile phase was 
exclusively acetonitrile and gradient system was slightly modified as shown in the table 
no. 4 
Table no: 4 Gradient programme (Trial 2) 
 
Time(min) %A %B 
0.00 95 5 
18.00 20 80 
19.00 95 5 
25.00 95 5 
 
Observation:  
 Peaks shapes were not good fronting of the amlodipine peak was observed. 
Retention time of amlodipine and valsartan were found to be 8.1 and 12.5 min 
respectively. 
 
iii. Trial 3:  
Buffer Preparation:  
2 ml triethylamine (TEA) was mixed with 1000 ml water and adjust the pH 3.0 
with ortho phosphoric acid. Then filtered through 0.22 µ nylon membrane filter and 
degassed.  
 
Mobile Phase Preparation: 
Mobile Phase A   : Buffer 
Mobile Phase B   : ACN 
 
Chromatographic Condition: 
Column & ID NO   : Symmetry C18, (4.6 × 150, 5 µ) 
Column temperature   : 35 oC   
Inj. Volume    : 10 µl 
Flow rate    : 1.0 ml/min  
λ max                                                : 237 nm 
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Gradient Programme: As shown in the table no. 5 
 
Table no. 5 Gradient programme ( trial 3) 
 
Time (min) %A % B 
0.01. 75 25 
12.00 10 90 
15.00 75 25 
20.00 75 25 
 
 
Fig. no. 10 Blank chromatogram for trial 3 
 
 
 
 
 
 
 
 
 
METHOD DEVELOPMENT                                                                                           CHAPTER-6  
 
K. M. COLLEGE OF PHARMACY       PHARMACEUTICAL ANALYSIS Page 44 
 
Fig. no. 11  Standard chromatogram for trial 3 
 
 
 Observation: 
 Peak shapes were not satisfactory. Retention time of amlodipine and valsartan 
were found to be 5.285 and 8.518 min respectively. Blank and standard chromatograms 
are shown in fig no. 10 and 11. 
 
iv. Trail No.4: 
Buffer Preparation:  
Weighed and transferred 1.36 gm KH2PO4 in to 1000 ml H2O and adjust the pH 
3.0 with ortho phosphoric acid. 
Mobile Phase Preparation: 
Mobile Phase A   : Buffer 
Mobile Phase B   : ACN 
Diluent    : Buffer : Methanol (1: 1) 
  
Chromatographic Condition: 
Column Name & ID NO  : Symmetry C18, (4.6 × 150, 5 µ) 
Column temperature   : 35 oC           
Flow rate    : 1.0 ml/min  
Inj. Volume    : 10 µl 
λ max     : 237 nm 
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Gradient Programme: As shown in the table no. 6 
 
Table no. 6 Gradient programme (Trial 4) 
 
Time (min) %A % B 
0.01. 75 25 
12.00 10 90 
15.00 75 25 
20.00 75 25 
  
 
Fig. no. 12 Blank chromatogram for trial 4 
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Fig. no. 13 Standard chromatogram for trial 4 
 
 
 
Observation: 
 Peak shape was not good in both standard and sample preparations. Retention 
time is acceptable. Theoretical plates were too less and asymmetry was more than the 
permitted limit. Blank and standard chromatograms are shown in fig no. 12 and 13. 
 
6.3. Optimization method: 
 
Preparation of Buffer: 
2.0 ml of triethylamine was transferred in to a beaker containing 1000 ml of water 
and mixed. The solution pH was adjusted to 3.0 ± 0.05 with ortho phosphoric acid, 
filtered through 0.22 µ membrane filter. 
Mobile phase A  : Buffer 
Mobile Phase B  : Acetonitrile 
Preparation of Diluent: 
Prepare a degassed mixture of buffer and methanol in the ratio of 50 : 50 v/v 
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Chromatographic conditions: 
Column    : Symmetry C18, (150 x 4.6 mm, 3.5 µ) 
Detector wavelength   : 237 nm  
Injection volume   : 10 µl 
Flow rate    : 1.0 ml/min 
Column oven temperature  : 35 oC 
Run time    : 20 min 
Gradient Programme: As shown in the table no. 7 
 
Table no.7 Gradient programme (optimized method) 
 
Time A% B% 
0 75 25 
12 10 90 
15 75 25 
20 75 25 
 
 
Preparation of standard stock solution: 
 Amlodipine besylate 70 mg and 64 mg of valsartan are weighed and transferred 
into 100 ml volumetric flask, sonicating for 10 min and diluted to volume with diluents 
and mixed.  
 
For 10 mg / 320 mg and 5 mg / 320 mg 
From the above standard solution 5 ml was pipetted and transferred into a 25 ml 
volumetric flask, diluted to volume with diluents and mixed. 
 
Preparation of sample solution: 
Assay tablets  
  The combination of AMBL and VAL are available in the ratio of 1:16, 1:32. The 
tablet taken for the assay contains 10 mg of AMBL and 320 mg of VAL. 
 Since the ratio of the combination exist in large difference. The dilution of the 
sample was carried out in two different stages A and B to get chromatographed 
appropriate peak area as shown in the table no.8 and chromatograms were shown in the 
fig. no. 15, 16 and 17. 
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Amlodipine and valsartan 10 mg/ 320 mg tablets dilution chart 
 
Standard preparation: 
 
                            
                   70 mg of AMBL       
                               Or                                           100   (Correction factor = 408/567.1)    
                      64 mg of VAL  
                                
 
                                                                                 5                            25 
The final concentration of AMBL and VAL were 100 ppm and 128 ppm respectively. 
 
                 20 ml methanol                          Degassed mixture of buffer: methanol in the ratio of  
                                                                                        50:50 v/v. 
 
 
 
 
 Sample preparation: 
 
                   20 mg of AMBL 
                                 Or                                          200 ml (A) 
                    640 mg of VAL                                 
 
 
 
                                                                            2                                     50 ml (B) 
 
The final concentration of AMBL and VAL were 100 ppm and 128 ppm respectively. 
              
                                                                    Degassed mixture of buffer: methanol in the ratio of  50:50v/v. 
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Fig. no. 14 Blank chromatogram for optimized method 
 
 
 
 
                  Fig. no. 15  Standard chromatogram for optimized method 
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Fig. no. 16 Amlodipine sample chromatogram for optimized method 
 
 
 
 
Fig. no. 17 Valsartan sample chromatogram for optimized method 
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Observation: 
 Peak shape was satisfactory in both standard and sample preparations. Retention 
time is acceptable. Blank, standard and sample chromatograms are shown in fig no. 14, 
15, 16 and 17. Peak area, % RSD and mean were shown in the table no. 8. 
 
Calculations: 
FOR AMLODIPINE (% Labeled amount) 
For Tablets assay / Blend assay  
For 10 mg / 320 mg and 5 mg / 320 mg 
 
 x  x   x x x 100 
 
For 10 mg /160 mg and 5 mg / 160 mg 
 
 x  x  x x x 100 
 
AT1 - Area count of amlodipine peak in sample solution. 
AS1 - Average area count of amlodipine peak obtained from five replicate           
                      injections of standard solution. 
Ws1 - Weight of amlodipine besylate working standard solution taken, in mg 
WT1 - Weight of sample taken, in mg. 
P1 -  % purity of amlodipine besylate working standard used.  
 
 
FOR VALSARTAN (% Labeled amount) 
For Tablet assay / Blend assay: 
For 10 mg / 320 mg and 10 mg/ 160 mg. 
 
 x  x   x x 100 
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AT2      - Area count of valsartan peak in sample solution. 
AS2 - Average area count of valsartan peak obtained from five replicate  
                      injections of standard solution. 
Ws2 - Weight of valsartan working standard solution taken, in mg 
WT2    - Weight of sample taken, in mg. 
P2 - % purity of valsartan working standard used.  
 
 Calculate the amount of each drug by using the following formula.   
 
                 Amlodipine = X X           
 
             Valsartan = X X  
Where  
AA - Average area counts of injections for amlodipine peak in the    
chromatograms of sample solution. 
ASA - Average area count of five replicate injections for amlodipine peak in the  
chromatogram of Standard solution. 
ASVAL - Average area counts of injections for valsartan peak in the chromatogram  
of sample solution.  
ASVAL - Average area counter of five replicate injections for valsartan peak in the  
chromatogram of standard solution. 
DS - Dilution factor of standard solution (weight ÷ dilution)  
DT - Dilution factor of sample solution  
P - Percentage purity of working standard used.  
 
 
    Content of each drug (mg/tablet)  
% Labeled Amount =                                                                    X 100 
     Label claim (mg)  
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Table no. 8 Data for assay in tablet formulations 
 
S. no. Sample name AMBL VAL 
RT Peak area RT Peak area 
1 
 
2 
 
3 
 
4 
 
Mean 
 
%RSD 
 
SD 
Assay stock spl-1 
 
Assay stock spl-2 
 
Assay stock spl-3 
 
Assay stock spl-4 
 
 
 
 
 
5.068 
 
5.068 
 
5.063 
 
5.080 
 
5.070 
 
0.1 
 
0.007 
2585376 
 
2584325 
 
2578138 
 
2586304 
 
2583535.89 
 
0.1 
8.288 
 
8.283 
 
8.273 
 
8.269 
 
8.278 
 
0.1 
 
0.009 
2660937 
 
2656499 
 
2678468 
 
2681350 
 
2669313.61 
 
0.5 
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7.1. System suitability 
           System suitability is the checking of a system to ensure system performance before or 
during the analysis of unknowns. Before performing any validation experiment, HPLC 
method and the procedure should be capable of providing data of acceptable quality. These 
tests are to verify that the resolution and repeatability of the system are adequate for the 
analysis to be performed. It is based on the concept that equipment, electronics, analytical 
operations and sample constitute an integral system that can be evaluated as a whole. System 
suitability parameters and recommendations are shown in the table no.9 
Table no. 9 System suitability parameters and recommendations 
S. 
No 
Parameters Recommendations 
1 Theoretical plates (N) >2000 
2 Tailing factor (T) ≤ 2 
3 Resolution (Rs) 
> 2 between peak of interest and the closest eluting 
potential interference 
4 Repeatability RSD ≤ 1% for N ≥ 5 is desirable 
5 Capacity factor (k1) > 2.0 
6 Relative retention Not essential as long as the resolution is stated 
 
Procedure: 
A standard solution was prepared by using amlodipine besylate and valsartan working 
standards as per test method and was injected ten times into the HPLC system. 
The system suitability parameters were evaluated from standard chromatograms by 
calculating the % RSD from ten replicate injections for amlodipine besylate and valsartan 
retention times and peak areas. Resulted chromatogram was shown in the chromatogram fig. 
no. 19.  
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Observation: The system suitability parameters were satisfactory and exhibited in table 
no.10. 
 
7.2. Specificity  
 Specificity is the ability to assess unequivocally the analyte in the presence of     
components which may be expected to be present. Typically these might include impurities, 
degradants, matrix, etc. 
 
Lack of specificity of an individual analytical procedure may be compensated by other 
supporting analytical procedure(s). 
This definition has the following implications:         
Identification: To ensure the identity for an analyte. 
Purity Tests: To ensure that all the analytical procedures performed allow an                    
accurate statement of the content of impurities of an analyte, i.e. related substances test, 
heavy metals, residual solvents content, etc. 
a. Placebo Interference: 
A study to establish the interference of placebo was conducted. Samples were prepared 
in triplicate by taking the placebo equivalent to about the weight in portion of test preparation 
as per the test method. Chromatogram of placebo did not show any additional peaks. This 
indicates that the excipients used in the formulation do not interfere in the assay of 
amlodipine besylate and valsartan tablets. Resulted chromatograms are shown in the fig.no. 
20. 
Acceptance criteria:  
No interference at the retention times of amlodipine besylate and valsartan. 
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The assay of amlodipine besylate and valsartan tablets is showing that the test method 
is precise shown in table no.12 for method precision.  
 
Fig no. 21 Amlodipine and valsartan sample chromatogram 
 
 
Observation:  
 % RSD of the amlodipine and valsartan tablet from six units was found to be 0.2, as 
shown in the table no. 12. 
 
Table no.12 Data for method precision 
S.NO AMBL VAL 
RT Peak area RT Peak area 
1 5.089 1932075 8.311 2768666 
2 5.077 1937803 8.294 2774111 
3 5.078 1941938 8.298 2780808 
4  5.08 1945530 8.302 2777299 
5 5.082 1945255 8.304 2782394 
Mean 5.081 1940519.91 8.302 2776655.4 
SD 5661.8 5661.84 0.006 5497.59 
%RSD 0.3 0.3 0.1 0.2 
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7.4. Accuracy: 
The accuracy of a method is the closeness of the measured value to the true value for 
the sample.  
 Accuracy criteria for an assay method is that the mean recovery will be 100 ± 2 % 
over the range of 95 % - 105 % at the target concentration. For impurity method, the mean 
recovery will be within 0.1 % absolute of the theoretical concentration or 10 % relative, 
whichever is greater for impurities in the range of 0.1-2.5 %  v/w. 
Accuracy of test method was carried out by spiking known amount of drug substance to 
get concentration of amlodipine besylate and valsartan 50 %, 100 % and 150 % of target 
concentration in triplicate for each level. Each solution was injected in triplicate. The average 
% recovery of amlodipine besylate and valsartan was calculated.  
Separately injected the blank and placebo of amlodipine besylate and valsartan into the 
system and chromatographed. 
Acceptance criteria:  
The mean % recovery of the amlodipine besylate and valsartan at each level should be 
in the range of 95 %-105 %. 
Observation:  
The recovery results indicating that the test method has an acceptable level of accuracy 
shown in table no: 13 and 14 
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Table no. 13  Accuracy data for amlodipine besylate 
 
 
 
 
Concentration 
of spiked level 
Amount added 
(ppm) 
Amount found 
(ppm) 
% 
Recovery 
Statistical analysis 
of % recovery 
 50.08 49.63 99.1 Mean 99.78 
50% sample 50.56 50.4 99.68 SD 0.534 
 50.03 49.53 100.1 %RSD 0.535 
 100.01 98.46 98.36 Mean 99.28 
100% sample 100.13 99.391 99.26 SD 0.462 
 100.23 100.07 100.15 %RSD 0.468 
 150.12 150.05 99.95 Mean 99.28 
150% sample 150.23 150.15 99.96 SD 0.447 
 150.3 149.94 99.76 %RSD 0.4471 
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Table no. 14  Accuracy data for valsartan 
 
 
 
 
 
 
Concentration 
of spiked level 
Amount 
added(ppm) 
Amount 
found (ppm) 
% Recovery
Statistical analysis 
of %  Recovery 
 64.58 64.32 99.59 Mean 9.67 
50% sample 64.98 64.17 98.75 SD 0.505 
 64.63 64.01 99.04 %RSD 0.595 
 128.86 127.23 99.07 Mean 99.39 
100% sample 129.03 128.76 99.79 SD 0.701 
 129.45 128.69 99.41 %RSD 0.698 
 192.56 192.36 99.89 Mean 100.22 
150% sample 193.98 191.64 98.79 SD 0.35 
 192.66 192.24 100.23 %RSD 0.249 
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7.5. Linearity:  
 Linearity of an analytical procedure is its ability (within a given range) to obtain test 
results which are directly proportional to the concentration (amount) of analyte in the sample. 
Linearity should be evaluated by visual inspection of a plot of signals as a function of analyte 
concentration or content.  If there is a linear relationship, test results should be evaluated by 
appropriate statistical methods.  For example, calculation of a regression line by the method 
of least square.  Therefore data from regression line itself may be helpful to provide 
mathematical estimates of the degree of linearity. Linearity was performed by preparing 
AMBL and VAL standard solutions in the range of 50-150% of target concentration (50%, 
60% 80%, 100% 120% and 150%). Measure the peak area response of solution at Level 1 and 
Level 6 six times and Level 2 to Level 5 two times.  
Acceptance criteria:  Correlation coefficient should be not less than 0.9990.  
% of RSD for Level 1 and Level 6 should be not more than 2.0 %. 
Observation:  
The correlation coefficient was found to be 0.999 and 1 for AMBL and VAL 
respectively. Refer tables 15 and16. From the above study it was established that the linearity 
of test method is from 50 % to 150 % of target concentration shown in linearity plots figure 
no. 22.  
Table no.15 Linearity data for amlodipine 
Linearity 
Level 
Concentration(ppm) Average area %RSD Statistical Analysis 
L1-50% 50.56 1292693.3 0.58 Slope 16028 
L2-60% 60.08 1551226.8 0.47 Y-intercept 25670 
L3-80% 80.45 2068302.4 0.36 
% of Y-
intercept 
0.132 
L4-100% 100.23 2585378.2 0.57 
Correlation 
Coefficient 
R2 
 
L5-120% 120.26 3102453.6 0.49 0.999 
L6-150% 150.5 3878068.2 0.52  
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Table no. 16  Linearity data for valsartan 
Linearity 
Level 
Concentration 
(ppm) 
Average 
area 
%RS
D 
Statistical Analysis 
L1-50% 64.3 1384334.6 0.45 Slope 16379 
L2-60% 76.8 
1661201.5
2 
0.35 Y-intercept 27595 
L3-80% 102.4 
2214935.3
6 
0.56 
% of Y-
intercept 
0.149 
L4-100% 128 2768669.2 0.58 
Correlation 
Coefficient R2 
 
L5-120% 153.6 
3322403.0
4 
0.39 1.00 
L6-150% 193.2 4153003.8 0.48  
 
Fig no. 22 Linearity graph amlodipine and valsartan 
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7.6. Ruggedness of test method:  
 The United States pharmacopoeia (USP) define ruggedness as the degree of 
reproducibility of test results obtained by the analysis of the same samples under a variety of 
normal test conditions such as different labs, different analysis, different lots of reagents etc.  
Ruggedness is a measure of reproducibility of test results under normal expected operational 
conditions from laboratory to laboratory and from analyst to analyst.  
a) System to system variability: 
System to system variability study was conducted on different HPLC systems under 
similar conditions at different times. Six samples were prepared and each was analyzed as per 
test method. The relative standard deviation for amlodipine besylate and valsartan were found 
to be below 2 % on the systems. Comparison of both the results obtained on two different 
HPLC systems variability.  
 
Acceptance Criteria:  
The % RSD of amlodipine besylate and valsartan from the six sample preparations 
should be not more than 2.0 %.  
The % recovery of amlodipine besylate and valsartan should be between 95.0 % to              
105 %.  
Observation: 
The %RSD was found within the limits were shown in table no: 17 and 18. 
 
                       
Table no. 17  Data for the ruggedness study in system-1 
Tablet ID 
% Assay Statistical Analysis 
AMBL VAL  AMBL VAL 
1 99.24 98.28 
Mean 98.878 99.29 
2 98.19 99.36 
3 98.34 99.78 
SD 1.01 0.68 
4 98.12 99.04 
5 100.5 100.03 %RSD 1.02 0.68 
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Table no. 18 Data for the ruggedness study in system-2 
Tablet ID 
% Assay Statistical Analysis 
AMBL VAL  AMBL VAL 
1 99.19 99.28 
Mean 98.834 98.838 
2 98.14 99.06 
3 99.32 98.78 
SD 0.698 0.48 
4 98.02 98.04 
5 99.5 99.03 %RSD 0.7 0.48 
 
 
b) Bench top stability of standard and Test preparation: 
 
A study to establish stability of amlodipine besylate and valsartan standards and test 
preparations on bench top was conducted over period of two days. Amlodipine besylate and 
valsartan test preparation spiked to target concentration are injected initial, 6.0 hr, 12 hr 
and18 hr. The difference in % of amlodipine besylate and valsartan from initial to 18hrs is 
within the limits. In the similar way standard preparations were injected initial, 6.0 hr and    
18 hr.  
 
Acceptance Criteria:  
 
The difference between initial and bench top stability sample for % RSD of amlodipine 
besylate and valsartan should be not more than 2.0.  
 
Observation:  
 
The % assay was found with the limits. Table no: 19 and 20 
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Table no. 19 Data for interday variation 
Tablet ID 
% Assay Statistical Analysis 
AMBL VAL  AMBL VAL 
1 99.54 99.34 
Mean 99.39 99.4 2 98.02 99.13 
3 99.87 101 
SD 1.05 0.592 4 101.02 99.76 
5 98.5 98.76 
% RSD 1.06 0.598 6 99.43 101.16 
 
 
Table no. 20 Data for intraday variation 
Tablet ID 
% Assay Statistical Analysis 
AMBL VAL  AMBL VAL 
1 99.14 99.38 
Mean 98.954 99.185 2 98.24 98.46 
3 98.77 99.78 
SD 0.732107 0.684 4 100.12 100.04 
5 98.5 99.9 % RSD 0.739845 0.69 
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7.7. Robustness: 
 
 Robustness of the proposed analytical method was evaluated by making deliberate 
changes in the chromatographic system method parameters, the standard solution and test 
solutions were injected for each of the changes made to access the robustness of proposed 
analytical method.  
   
i) Effect of variation of flow rate: 
 
Mobile phase flow rate as per proposed analytical method is 1.0 ml/min. Change in 
flow rate was made at a level of 10 percentages i.e. at 0.9 and 1.1 ml/min. The effect due to 
change in flow rate on the system suitability parameters are compared. Results are tabulated 
in table no. 21.   
 
Acceptance Criteria:  
The tailing factor of amlodipine and valsartan standards should be not more than 2.0 for 
variation in flow.  
Table no.21 Data for variation in flow rate 
Parameters 
AMBL VAL 
RT Peak area RT Peak area
Normal (1.0 ml/min, %RSD-0.04, 0.5) 5.1              2583537 8.2       2669313 
Flow rate 0.9 ml/min 7.3               2623612 10.7        2854365
Flow rate 1.1 ml/min 4.5               2183133 6.3        2296323
%RSD                       0.205               0.27 
 
Observation:  
 
The % RSD for amlodipine and valsartan are found to be within the limits as shown in 
the table no. 21. 
 
ii) Effect of Variation of temperature:  
The column oven temperature as per proposed analytical method is 35 oC. Change in 
column oven temperature by 5 oC both by increasing and decreasing fashion. The effects due 
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to change column oven temperature on the system suitability parameters are compared. 
Results are tabulated in table no. 22 and 24. 
 
Acceptance criteria:  
 
The % RSD of amlodipine and valsartan standard and sample solutions should be not 
more than 2.0 for variation in temperature.  
 
Table no.22 Data for variation in column temperature 
Parameters 
AMBL VAL 
RT Peak area RT Peak area
 Normal (35 °C, % RSD-0.04, 0.5) 5.1              2583537 8.2       2669313 
Column temperature 30 °C 5.2               2482427    8.3        2774128
Column temperature 40 °C 5.1              2468953 8.1        2796459
%RSD                       0.095               0.055 
 
Observation: 
 
Increase in temperature resulted in early elution of all two active ingredients. Decrease 
in temperature resulted in late elution of all two actives but still within the proposed run time 
as shown in the table no. 22 and 24. 
 
iii) Effect of variation in pH 
 
  The pH employed for the analytical method is 3.0. To study the effect of pH the buffer 
pH was changed to 2.8 and 3.2. The effects due to change pH on the system suitability 
parameters are compared. Results are tabulated in table no. 23.  
 
Acceptance criteria:  
 
The % RSD Factor amlodipine and valsartan were found to be within the limits as 
shown in the table no. 23 and 24. 
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Table no.23  Data for variation in pH 
Parameters 
AMBL VAL 
RT Peak area RT Peak area
 Normal (pH 3.0, %RSD-0.04, 0.5) 5.1              2583537 8.2       2669313 
Buffer pH 2.8 5.9              2543198   9.6       2687432
Buffer pH 3.2 4.9              2574944 8.0      2753421 
%RSD                       0.245               0.255 
 
Observation: 
Increase in pH resulted in early elution of all two active ingredients. Decrease in pH 
resulted in late elution of all two actives but still within the proposed run time as shown in 
table no. 23 and 24. 
 
Table no. 24  Remarks in robustness parameters 
 
Parameters 
  
Optimum 
range 
 
Conditions 
in 
procedure 
 
Remarks 
 
 
Flow rate 
ml/min 
 
 
 
       0.9-1.1 
 
 
 
1 
Increase in flow rate resulted in 
early elution of all two active 
ingredients. Decrease in flow rate 
in late elution of all three actives 
but still within the proposed run 
time.  
 
 
 
Temperature 
 
 
 
30-40 oC 
 
 
 
35 oC 
Increase in temperature resulted in 
early elution of all two active 
ingredients. Decrease in 
temperature resulted in late elution 
of all two actives but still within 
the proposed run time.  
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pH 
 
2.8-3.2 
 
3.0 
Increase in pH resulted in early 
elution of all two active 
ingredients. Decrease in pH 
resulted in late elution of all two 
actives but still within the 
proposed run time 
 
CONCLUSION: From the above results it is concluded that the method was robust.  
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8. RESULTS AND DISCUSSION 
Combination therapy in the treatment of hypertension as an appropriate treatment 
option is receiving boarder acceptance amongst the clinical community. Amlodipine is an 
effective of hypertension in once daily doses of 2.5 mg - 10 mg while valsartan is effective in 
doses of 80 mg – 320 mg. 
 Only very few HPLC estimations have been reported in the literature for the 
determinations of amlodipine and valsartan present in bulk, formulations and biological 
fluids.   
 
Method development: 
The developed method has an advantage of determination of AMBL and Val by RP-
HPLC. HPLC determination was carried out on a reversed phase C18 column. Following 
tables give the results of the method development, quantitation and validation parameters.  
  
Table no. 25 Validation parameters and acceptance criteria for AMBL and VAL 
S. No Parameters AMBL VAL 
Acceptance 
Criteria 
1. SPECIFICITY 99.12%        99.18% No interference of excipients. 
2. LINEARITY 1                 0.999 0.99 
3. ACCURACY 98.4%         100.4% 95 – 105% 
 
 
4. 
           PRECISION 
 
System Precision 
 
   0.86%          0.58% 2% (RSD) 
 
Method Precision    0.1%              0.2% 2% (RSD) 
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5. 
 
 
RUGGEDNESS 
 
 
 
  99.17%        99.29% 
 
   0.895%       0.644% 
 
 
95-105% 
 
          2% (RSD) 
 
 
 
 
 
 
 
6. 
 
 
 
 
 
 
 
ROBUSTNESS 
a) Change in flow rate 
• 0.9 ml/min 
 
• 1.0 ml/min 
 
 
 
 
 
0.34%        0.42% 
 
0.07%           0.12% 
 
 
2% (RSD) 
 
b) change in the buffer 
pH 
 
• 2.8 
 
• 3.2 
 
 
 
 
 
0.10%       0.14% 
 
0.39%         0.37% 
 
 
2%(RSD) 
c) Change in column 
temperature 
• 30 oC 
 
 
• 40 oC 
 
 
 
 
0.06%         0.04% 
 
0.13%         0.07% 
2% (RSD) 
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Table no.26  Assay method 
 
 
 
 
 
7. 
SYSTEM SUITABILITY 
a) Theoretical Plates 
 
b)     Tailing factor 
 
c) RSD 
 
7172.23          11750.61 
 
1.08               1.11 
 
0.13                0.10 
 
NLT 2000 
 
NMT 2 
 
NMT 2.0% 
S. 
No. 
Content 
Label 
claim 
(mg) 
Peak area RT 
Percentage 
Content 
1. 
2. 
 
AMBL 
VAL 
10 mg 
320 mg 
2583535.89
2669313.61
5.07 
8.2 
 
99.28 % 
99.39 % 
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9. CONCLUSION 
More rapid, precise, specific, sensitive, economic and reproducible gradient reverse 
phase HPLC method was developed and validated for simultaneous determination of 
amlodipine besylate and valsartan tablets. The method was validated for specificity, linearity, 
and precision as per ICH guidelines.  
Chromatographic conditions: 
Column    : Symmetry C-18, (150 x 4.6 mm, 3.5 µ) 
Flow rate    : 1.0 ml/min 
Detector wavelength   : 237 nm  
Injection volume   : 10 µL 
Column oven temperature  : 35 oC 
Run time    : 20 min 
 
The RP-HPLC method for AMBL and VAL detector wave length is 237 nm, the 
beer’s law was obeyed in the concentration of 100 ppm of AMBL and 128 ppm of VAL and 
retention time found to be 5.06 and 8.28 min respectively. 
 
Conclusion and recommendations:  
 
  A new method was developed for the quantification of AMBL and VAL in combined    
tablet formulation. This method seems to obey the validation parameters and cost effective. 
This method can be routinely employed for the analysis of this combination. The reason 
behind selection of two different categories of antihypertensive drugs was also justified 
properly because of synergistic effect on lowering of blood pressure and reduction of side 
effects of one drug by another. Side effects of the individual drugs can be mitigated by using 
a complementary agent rather than increasing the dose of a single agent. 
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GLOSSARY 
 
1. Degassing: The process of removing dissolved gas from the liquid mobile phase 
before or during use. Degassing is done by heating, by vacuum, or by helium purging. 
2. Drift: The change in the baseline value over time, expressed line mathematically as 
the slope of the least line squares line fitted to the base line in a specified region 
chromatogram. 
3. Eluent:  Mobile phase used to perform a chromatographic separation. The liquid that 
exists through a chromatographic column during a separation. 
4. Equilibration: The process of bringing a chromatographic solvent (solvent, column 
and interactive surfaces) to a thermally and chemically stable, usually indicated by a 
drift_ free base line. 
5. External standard: A separate sample that contains known quantities of the same 
compounds that are in unknown sample. External standards are used for quantitation 
by matching the detector response of a component peak to a point on a calibration 
curve for that component. The calibration curve is generated from a separately 
processed standard (or a set of standards). 
6. Fronting peak: An asymmetrically shaped chromatographic peak in which the front 
part of the peak (before the apex) contains more area than the rear of the peak. The 
asymmetry factor for fronting peak has value less than one. The opposite of fronting 
peak is a tailing peak. 
7. Fused peak: Two or more no baseline – resolved peaks in a chromatogram that share 
the same base line, the same base line start and end points, and the same slope and 
offset. 
8. Gradient elution: Also called as solvent programming, a technique for decreasing the 
separation time by increasing the mobile phase strength over time during a 
chromatographic separation. Gradients can be continuous or stepwise. Binary (2- 
solvent), ternary (3-solvent) and quaternary (4- solvent) gradients are used routinely 
in HPLC. 
9. Integration: The mathematically process of calculating an area such as a 
chromatographic peak that is bounded in a part or in a whole by a curved line. 
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10. Isocratic: The condition in which the solvent composition, flow rate and the 
temperature are constant during a chromatographic run, the condition in which the 
solvent composition is constant during a chromatographic run. 
11. Linearity: The condition in which detector response is directly proportional to the 
concentration or amount of a component over a specified range of component 
concentration or amounts. A calibration curve is a straight line when the standard 
concentration is within the linear response range of the detector. The chromatography, 
accurate quantitation requires linearity of the detector response over the range of 
actual sample concentration or amounts. 
12. Mobile phase: The fluid (gas or liquid) that carries solutes through a 
chromatographic column. In lc the liquid that is pumped through the fluid path of the 
chromatographic system and into which the samples are injected. 
13. Plate count: A measure of the observed chromatographic resolution based on its 
equivalency to the number of the theoretical plates that would provide the same 
resolution.  
14. Resolution: The extent to which a chromatographic column separates components 
from each other. Mathematically defined, resolution is the difference between the 
peak retention time of a selected peak and the peak preceding it’s multiplied by a 
constant of 1.178, and then divided by the sum of the peak widths at 50% of peak 
height. It is used to monitor the separation of eluting components and to establish 
system efficiency. 
15. Retention time: The time that elapses between the injection of a sample and the 
appearance of the peak maximum of a component in a sample. 
16. Rt ratio: The retention time of a component divided by the retention time of its 
reference peak. 
17. System suitability:  An application that applies a set of standard criteria to test if an 
entire chromatographic system and the methodology are working within acceptable 
limits. Empower software bases the system suitability testes on standard laboratory 
calculations, including United States pharmacopoeia (USP) guidelines and 
calculations. Empower software procedures reports showing statistical accuracy and 
reproducibility of the chromatographic system data. 
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18. Tailing factor: A measure of peak symmetry where a symmetrical peak has a tailing 
factor of 1. As tailing increases peak symmetry increases for system suitability the 
tailing factor is the width of the peak at 5% height divided by two times the distance 
from the peak maximum to the leading edge of the peak (where the distance is 
measured at point 5% of the peak height from the baseline). 
19. Capacity factor: A chromatographic parameter that measures retention time of a 
sample molecule relative to the column dead volume. 
20. Acceptance criteria: Numerical limits ranges or other suitable for acceptance of the 
results of analytical procedures. 
21. Detection limit: The detection limit of an individual analytical procedure is the 
lowest amount of analyte in a sample that can be detected but not necessarily 
quantitated as an exact value. 
22. Drug product: A finished dosage form, for example a capable tablet or solution that 
contains a drug substance, but not necessarily in association with one or more other 
ingredients. 
23. Drug substance: Active ingredient: an active ingredient that is intended to furnish 
pharmacological activity or other direct effect the structure or any function of the 
human body. The active ingredient does not include intermediates used in the 
synthesis of such ingredient. The term includes those components that may undergo 
chemical change in the manufacture of the drug product and be present in the drug 
product in a modified form intended to furnish the specified activity or effect.  
24. Reagent: For analytical procedures any substance used in a reaction for the purpose 
of detecting measuring examining or analyzing other substance. 
25. Specification: The quality standards (i.e.., tests, analytical procedures, and acceptance 
criteria) provided in an approved application to confirm the quality of the drug 
substances, drug products, intermediates, raw materials, reagents, and other 
components including container closure systems, and in-process materials. 
26. Spiking: The addition of small known amount of a known compound to a standard, 
sample, or placebo, typically for the purpose of confirming the performance of an 
analytical procedure of an analytical procedure or the calibration of an instrument. 
27. Working standards: A standard that is qualified against and used instead of the 
reference standard (also known as in-house or secondary standards). 
